Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Labcorp Reports Strategic Expansion Of Its Precision Oncology Portfolio

Author: Benzinga Newsdesk | April 08, 2024 07:11am

Labcorp is expanding its portfolio of solutions that support the development of novel therapies for oncology with the launch of its proprietary platform for molecular residual disease (MRD), Labcorp Plasma Detect, enhancement of its circulating tumor DNA (ctDNA) genomic profiling solution Labcorp Plasma Complete, and continued investment in expanding its capabilities in cell and gene therapy.

Posted In: LH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist